The Complete Neurotoxin Comparison Guide: Botox vs. Dysport vs. Xeomin vs. Daxxify vs. Letybo

While 'Botox' has entered the cultural lexicon as a generic term for wrinkle-relaxing injections, modern medical spas offer five distinct FDA-approved botulinum toxin type A pharmaceuticals: Botox Cosmetic (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Daxxify (daxibotulinumtoxinA-lanm), and Letybo (letibotulinumtoxinA-wlbg).

Each product shares the identical underlying therapeutic mechanism of action: cleaving the SNAP-25 intracellular protein within cholinergic presynaptic nerve terminals, inhibiting the vesicular exocytosis of acetylcholine, and temporarily relaxing targeted facial muscles.

However, they differ significantly in molecular weight, accessory protein coatings, diffusion halos, cellular stabilization, onset speed, and clinical duration. Understanding these pharmacological differences allows patients and providers to select the ideal neuromodulator for specific facial vectors.

One of the most frequent points of patient confusion is dosage comparison across brands. In the United States, botulinum toxin units are not standardized across manufacturers; a 'unit' represents an assay-specific biological activity measure (the median lethal dose, or LD50, in a murine model) determined by each pharmaceutical maker's proprietary laboratory testing.

The 1:1 Biological Equivalents: Clinical consensus recognizes a 1:1 dosing equivalence between Botox, Xeomin, and Letybo. If your glabella frown lines require 20 units of Botox, you will achieve virtually identical neuromuscular blockade with 20 units of Xeomin or 20 units of Letybo.

The Dysport Ratio (2.5 to 3.0 : 1): Dysport is formulated using a different potency assay. Clinical trials demonstrate that it requires approximately 2.5 to 3.0 units of Dysport to equal the biological effect of 1 unit of Botox or Xeomin. Therefore, a standard 20-unit Botox glabella treatment corresponds to 50 to 60 units of Dysport. Patients seeing quotes for '60 units of Dysport' are not receiving triple the medication; they are receiving the biological equivalent of 20 units of Botox.

Daxxify Dosing: In its FDA registrational trials, Daxxify evaluated 40 units for the glabellar complex (a 2:1 ratio relative to standard 20-unit Botox protocols), delivering its characteristic 6-to-9-month duration.

Why does a neurotoxin stop working for some long-term patients? The answer often lies in molecular structure and immune response.

Complexed Toxins (Botox, Dysport, Letybo): The active 150 kDa neurotoxin core is surrounded by accessory hemagglutinin and non-hemagglutinin non-toxic proteins, yielding a 900 kDa molecular complex. While these protective proteins historically shielded the toxin during manufacturing, your immune system can recognize them as foreign foreign antigens, occasionally developing neutralizing antibodies that render future treatments ineffective ('toxin resistance').

The 'Naked' Neurotoxin (Xeomin): Merz Pharmaceuticals utilizes an additional chromatographic purification step that strips away all accessory complexing proteins, leaving only the pure 150 kDa active therapeutic neurotoxin. Xeomin carries the lowest documented rate of neutralizing antibody formation, making it the premier clinical choice for patients experiencing declining efficacy with other brands.

Peptide Stabilization (Daxxify): Revance Therapeutics replaces human and animal donor proteins entirely with a synthetic, positively-charged 35-amino-acid peptide (RTP004). This peptide enhances neuromuscular anchoring and extends clinical duration without biological protein additives.

When an injector administers neurotoxin, the solution diffuses in a microscopic radius (or 'halo') around the needle entry point before binding to motor endplates.

Broad Diffusion (Dysport): Dysport exhibits a wider, more feathery diffusion radius. This makes Dysport exceptionally effective for broad, hyperdynamic forehead musculature (the frontalis) and expansive neck platysmal bands, creating an airbrushed, natural softening without frozen patchiness. However, injectors must exercise extreme caution when treating near the orbital rim to avoid eyelid ptosis.

Tight, Localized Diffusion (Botox, Xeomin, Letybo, Daxxify): These agents remain tightly focused at the injection vector. They are the clinical instruments of choice for hyper-precise micro-tox indications: crow's feet near the lateral canthus, gummy smile reduction (LLSAN muscle), bunny lines along the nasal bones, depressor anguli oris (DAO) downturned mouth corners, and upper lip flip injections.

Patients planning treatments ahead of weddings, photoshoots, or public speaking engagements must carefully align product onset timelines with their event dates:

Fastest Onset (Dysport & Letybo): Initial muscle weakening is commonly observed within 48 to 72 hours, reaching comprehensive relaxation by day 5 to 7. If you have an event in 7 to 10 days, Dysport or Letybo provide the most reliable rapid onset.

Standard Onset (Botox & Xeomin): Noticeable softening begins between days 3 and 5, with full clinical stabilization reached at day 10 to 14. An injector should never evaluate or retouch Botox before the full 14-day mark.

Standard Longevity (3 to 4 Months): Botox, Dysport, Xeomin, and Letybo consistently deliver 90 to 120 days of clinical muscle relaxation in most individuals.

Extended Longevity (6 to 9 Months): Daxxify's proprietary peptide formulation provides a median duration of 6 months in Phase 3 trials, with 25% of patients maintaining wrinkle control at 9 months.